<code id='11435CAC31'></code><style id='11435CAC31'></style>
    • <acronym id='11435CAC31'></acronym>
      <center id='11435CAC31'><center id='11435CAC31'><tfoot id='11435CAC31'></tfoot></center><abbr id='11435CAC31'><dir id='11435CAC31'><tfoot id='11435CAC31'></tfoot><noframes id='11435CAC31'>

    • <optgroup id='11435CAC31'><strike id='11435CAC31'><sup id='11435CAC31'></sup></strike><code id='11435CAC31'></code></optgroup>
        1. <b id='11435CAC31'><label id='11435CAC31'><select id='11435CAC31'><dt id='11435CAC31'><span id='11435CAC31'></span></dt></select></label></b><u id='11435CAC31'></u>
          <i id='11435CAC31'><strike id='11435CAC31'><tt id='11435CAC31'><pre id='11435CAC31'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:leisure time    Page View:74471
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In